Tenax Therapeutics announces positive oral levosimendan data in PH-HFpEF patients at HFSA meeting

TENAX THERAPEUTICS, INC.

18 PH-HFpEF patients transitioned from IV to oral levosimendan with no serious adverse events reported.
6-minute walk distance improved by mean 13.1 m; BNP decreased by mean 133.3 pg/dL; NT-proBNP decreased by 239.4 pg/dL.
KCCQ overall summary score improved 3.7 points; physical and clinical summary scores also improved.
Oral formulation at 3-4 mg/day deemed safe and effective for chronic use, supporting Phase 3 testing.
Data presented at HFSA Scientific Sessions 2022; investigators concluded oral levosimendan is well tolerated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.